Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Simmons, John K., Michalowski, Aleksandra M., Gamache, Benjamin J., DuBois, Wendy, Patel, Jyoti, Zhang, Ke, Gary, Joy, Zhang, Shuling, Gaikwad, Snehal, Connors, Daniel, Watson, Nicholas, Leon, Elena, Chen, Jin-Qiu, Kuehl, W. Michael, Lee, Maxwell P., Zingone, Adriana, Landgren, Ola, Ordentlich, Peter, Huang, Jing, Mock, Beverly A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/
https://ncbi.nlm.nih.gov/pubmed/28522584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados